anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Partnership HealthPlan of California (PHC) pays primary care physicians (PCPs) to discuss and document ACP with Medi-Cal beneficiaries aged 65 and older and those younger than 65 with a life-limiting illness (usual care). The control condition, or "enhanced usual care," adds a packet of educational information about ACP and access to the PREPARE website and verbal encouragement by their PCP delivered during a routine clinic visit to usual care.
PURPOSE:To obtain the titled easily producible capsule drug having sufficiently high buoyancy and strength, by adding a drug-active component to molten polyethylene glycol, oil and fat, etc., filling the mixture in a hard capsule body soluble in stomach and closing the body with a cap insoluble in stomach leaving a space in the capsule. CONSTITUTION:Molten polyethylene glycol and/or oil and fat (e.g. cacao fat, stearic acid, cetyl alcohol, etc.) is mixed with a drug-active component, preferably an oral drug desired to have prolonged activity (e.g. amoxicillin, cephalexin, etc.) or a polyethylene glycol or an oil or fat is mixed with a drug-active component under melting. The mixture is filled in a body of a hard capsule soluble in stomach and the body is closed with a hard capsule cap insoluble in stomach in a manner to leave a space (5-40% of the whole inner volume) in the capsule.
NAP at MTD (10 mcg/kg/day) and durvalumab (1120 mg) will be given for 6 cycles after a single dose of pre-treatment of obinutuzumab (1000 mg/day) on D-7. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
Introduction: ICP is commolnly manifested in the 2nd and especially in the 3rd trimester of pregnancy. Pathogenesis of ICP is multifactorial implicating genetic, environmental and hormonologic factors. Prevalence of ICP varies. In certain populations in latin America occurrence of ICP is up to 15% of pregnancies. In Caucasian populations incidence of ICP is approximately 1% of pregnancies. Data for the Greek population are scarce. Genes ABCB4 and ABCB11 that are encoding transport proteins in the hepatocyte are implicated in the pathogenesis of ICP.

Aim of the Study: To study the genetic polymorphisms in pregnant women with ICP and in their first degree relatives Patients and Methods: To recruit 100 women with ICP. Analyze the occurrence of 11 SNP's in ABCB11 and ABCB4 genes in women with ICP. As control group will be used pregnant women without ICP or known hepatic disease. In these women the same analysis for SNP's as in women with ICP will be performed. Exclusion criteria: women with known hepatic disease ( HBV, HCV, HIV, HEV, Autoimmune Hepatitis, Drug induced liver injury, cirrhosis) and women with pregnancy related liver disease (pre-eclampsia, acute fatty liver of pregnancy or HELLP syndrome) Inclusion criteria: pregnant women with ICP. Detailed report of medical history, laboratory and clinical data regarding women and the pregnancy. Follow up of laboratory values before and after the begging of treatment with UDCA.
INTRODUCTION: Despite improved management of traumatic brain injury (TBI), it still leads to lifelong sequelae and disability, particularly in children. Chronic neuroinflammation (the so-called tertiary phase), in particular, microglia/macrophage and astrocyte reactivity, is among the main mechanisms suspected of playing a role in the generation of lesions associated with TBI. The role of acute neuroinflammation is now well understood, but its persistent effect and impact on the brain, particularly during development, are not. Here, we investigated the long-term effects of pediatric TBI on the brain in a mouse model.
METHODS: Pediatric TBI was induced in mice on postnatal day (P) 7 by weight-drop trauma. The time course of neuroinflammation and myelination was examined in the TBI mice. They were also assessed by magnetic resonance, functional ultrasound, and behavioral tests at P45.
RESULTS: TBI induced robust neuroinflammation, characterized by acute microglia/macrophage and astrocyte reactivity. The long-term consequences of pediatric TBI studied on P45 involved localized scarring astrogliosis, persistent microgliosis associated with a specific transcriptomic signature, and a long-lasting myelination defect consisting of the loss of myelinated axons, a decreased level of myelin binding protein, and severe thinning of the corpus callosum. These results were confirmed by reduced fractional anisotropy, measured by diffusion tensor imaging, and altered inter- and intra-hemispheric connectivity, measured by functional ultrasound imaging. In addition, adolescent mice with pediatric TBI showed persistent social interaction deficits and signs of anxiety and depressive behaviors.
CONCLUSIONS: We show that pediatric TBI induces tertiary neuroinflammatory processes associated with white matter lesions and altered behavior. These results support our model as a model for preclinical studies for tertiary lesions following TBI.
BACKGROUND: With the increase of environmental pollution and atypical pathogen infections, the incidence of cough variant asthma (CVA) has been increasing annually, making it a pressing issue of the medical community. This study aims to observe the ameliorative effect of curcumin on a rat model of cough variant asthma.
METHODS: A rat model of cough variant asthma was induced by sensitization with ovalbumin combined with aluminum hydroxide (Al(OH)3), followed by repeated excitations. The drug was administered on the day of the initial nebulized attack, and gavage was administered for 14 d. Pathological changes in the lung tissues were observed, along with the assessment of cough susceptibility and airway resistance. The number of inflammatory cell eosinophils and leukocytes were determined in alveolar lavage fluid. Additionally, serum inflammatory factors and lung tissues Matrix Metalloproteinase-9 (MMP-9) protein were assessed. The level of M1/M2 macrophages was also detected.
RESULTS: Following the administration of curcumin, there was reduced inflammatory infiltration, less disordered arrangement of the lung tissue, and decreased abnormal proliferation of lung tissues in cough variant asthma rats compared to the model group. Curcumin treatment led toa notable reduction in cough frequency, a significant decrease in pro-inflammatory factor concentration levels in serum and inflammatory cell counts in the alveolar lavage fluid, and a marked increase in anti-inflammatory factor levels (p < 0.05). Additionally, curcumin administration led to a significant increase in M2-type macrophage levels, while simultaneously decreasing the levels of M1-type macrophages (p < 0.05).
CONCLUSIONS: The administration of curcumin effectively ameliorates ovalbumin-induced airway inflammation in cough-variant asthma rats. This effect is attributed to modulating macrophage polarization towards the anti-inflammatory M2 phenotype, thereby reducing airway inflammation, airway hyperresponsiveness, and lung tissue injury.
Techniques for monitoring a patient for the occurrence of an arrhythmia are disclosed. A computing system generates sample probability values by applying a machine learning model to sample patient data. The machine learning model determines respective probability values indicative of a probability of the arrhythmia occurring during each respective time window. The computing system outputs a user interface including graphical data based on the sample probability values, and receives, through the user interface, an indication of a user input for selecting a probability threshold for a patient. The computing system receives patient data for the patient and applies the machine learning model to the patient data to determine a current probability value. In response to determining that the current probability exceeds the probability threshold for the patient, the computing system generates an alert indicating the occurrence of the arrhythmia that the patient may have experienced.
The link between neuroinflammation and depression is a subject of growing interest in neuroscience and psychiatry; meanwhile, the precise mechanisms are still being unrevealed. However, glial cell activation, together with cytokine level elevation, suggests a connection between neuroinflammation and the development or exacerbation of depression. Glial cells (astrocytes) communicate with neurons via their extracellular neurotransmitter receptors, including glutamate receptors NMDARs. However, these receptor roles are controversial and enigmatic in neurological disorders, including depression. Therefore, we hypothesized whether NMDAR subnit NR2C deletion in the astrocytes exhibited anti-depressive effects concurrent with neuroinflammation prevention. To assess, we prepared astrocytic-NR2C knockout mice (G-2C: GFAPCre+Grin2Cflox/flox), followed by LPS administration, behavior tests, and biochemical analysis. Stimulatingly, astrocytic-NR2C knockout mice (G-2C) did not display depressive-like behaviors, neuroinflammation, and synaptic deficits upon LPS treatment. PI3K was impaired upon LPS administration in control mice (Grin2Cflox/flox); however, they were intact in the hippocampus of LPS-treated G-2C mice. Further, PI3K activation (via PTEN inhibition by BPV) restored neuroinflammation and depressive-like behavior, accompanied by altered synaptic protein and spine numbers in G-2C mice in the presence of LPS. In addition, NF-κB and JNK inhibitor (BAY, SP600125) treatments reversed the effects of BPV. Moreover, these results were further validated with an NR2C antagonist DQP-1105. Collectively, these observations support the astrocytic-NR2C contribution to LPS-induced neuroinflammation, depression, and synaptic deficits.
Participants in the McKenzie exercises for neck with cervical and scapulothoracic stabilization exercises group will receive a six-week exercise program that includes the McKenzie exercise protocol for neck pain and cervical and scapulothoracic stabilization exercises, performed under the supervision of a physiotherapist in the outpatient clinic. The program consists of three 30-45 minute sessions per week for a total of 18 sessions over six weeks. Participants will perform the McKenzie exercise protocol for neck pain first, followed by cervical and scapulothoracic stabilization exercises. Stabilization exercises aim to improve strength, endurance, and neuromuscular control of the cervical and scapulothoracic muscles. Participants will be instructed to perform the exercises at home as part of a home exercise program to ensure proper technique and consistency. This group receives both the McKenzie exercise protocol for neck pain and cervical and scapulothoracic stabilization exercises.
A process is described whereby a back-crossing protocol is used to create cannabis plants which are further standardized into medicinal products. A specific lighting regime is first used to bring a cloned plant to the vegetative stage followed by treatment with defined type of Gibberellic Acid (GA3) which stimulates sex reversal; from a female to a male. The pollen from this new male is used to pollenate the mother plant with her own pollen. This procedure creates a new variety of true breeding plant with a reproducible genome, which can be cloned into more plants. Confirmation of reproducibility is achieved us Gas Chromatography/ Mass Spectroscopy (GC/MS) to determine the Cannabinoid Profile of the pollenated plant. This cannabinoid profile is used as an index for the type of medicinal product which can be produced. Once this profile is established the raw material is gound into a powder, the cannabinoid profile is re-verified and the powder can be used as a medicine for symptom relief from many different ailments such as epileptic siezures, glaucoma, nausea/pain, multiple sclerosis tremors, migraine, fibromyalgia, hepatitis, depression, anorexia, anxiety. Route of administration of this powder can be made either oral or by smoking.
PROBLEM TO BE SOLVED: To obtain an aerosol medicine used for the oral inhalation treatments of airway passage and lung diseases, such as asthma by including mometasone furoate. SOLUTION: This aerosol medicine contains mometasone furoate preferably in the form of dry powder. Therein, the mometasone furoate does substantially not exist in blood at a systemic level, and the aerosol medicine is used for the first treatment of asthma once a day or the maintenance treatment of the asthma by oral inhalation preferably for allowing the action of the medicine to rapidly start. The medicine is preferably administered at a daily dose of 10-2,000 μg. The medicine uses the aqueous suspension of the mometasone furoate for the preparation of the medicine rapidly starting the action on the treatment of allergic rhinitis or seasonal rhinitis. The medicine is used for treating the corticosteroid-responding diseases of upper airway passage or lower airway passage and/or lung on patients suffering the corticosteroid-responding diseases.
Tracheostomies are indicated in children to facilitate long-term ventilatory support, aid in the management of secretions, or manage upper airway obstruction. Children with tracheostomies often experience ongoing airway complications, of which respiratory tract infections are common. They subsequently receive frequent courses of broad-spectrum antimicrobials for the prevention or treatment of respiratory tract infections. However, there is little consensus in practice with regard to the indication for treatment/prophylactic antimicrobial use, choice of antimicrobial, route of administration, or duration of treatment between different centers. Routine antibiotic use is associated with adverse effects and an increased risk of antimicrobial resistance. Tracheal cultures are commonly obtained from pediatric tracheostomy patients, with the aim of helping guide antimicrobial therapy choice. However, a positive culture alone is not diagnostic of infection and the role of routine surveillance cultures remains contentious. Inhaled antimicrobial use is also widespread in the management of tracheostomy-associated infections; this is largely based on the theoretical benefits of higher airway antibiotic concentrations. The role of prophylactic inhaled antimicrobial use for tracheostomy-associated infections remains largely unproven. This systematic review summarizes the current evidence base for antimicrobial selection, duration, and administration route in pediatric tracheostomy-associated infections. It also highlights significant variation in practice between centers and the urgent need for further prospective evidence to guide the management of these vulnerable patients.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use having melanogenesis inhibitory action and tyrosinase activity inhibitory action, thus excellent in mitigating pigmentation after suntan, freckles and chloasma, excellent in skin whitening effect, and also excellent in safety. SOLUTION: This skin preparation for external use contains, as active ingredient(s), 0.001-20 (pref. 0.01-10, more pref. 0.1-7)wt.% of compound(s) of formula I and/or formula II. This skin preparation can be made into formulations such as cream, ointment, gel, lotion, milky lotion, stick, pack, or organic solvent solution through blending the active ingredient(s) with, according as appropriate, commonly used ingredients such as moisturizing agent, antioxidant, oily ingredient, UV rays absorber, surfactant, thickening agent, alcohols and other skin whitening agent. The respective compounds of formula I and formula II have skin whitening effect greater than those for hydroquinone. These compounds have been known, and can be isolated from relevant plants.
Strains of influenza virus are developed from naturally occurring strains by submitting the natural strains to the following cycle of operations na) prodn. of a homologous serum from the viral strain; (b) determination of the dosage of this serum neutralising in vitro the normal development of a culture of the same virus; c) prodn. of n of the cultures being sufficiently great that the prodt. of the initial viral concn. and n at least equals the rate of mutation of the cultured virus while at the same time the probability of forming two mutants is practically negligible, the amt. of serum used being greater than that required for the neutralisation but is such that 1 + p of the n cultures developed, where p is a whole no. which is a function of the mutation rate, and is small, compared to n, so that any growth will be that of a mutant, and d) examining each of the 1 + p cultures by haemagglutination inhibition tests, to determine which of them is the most advanced mutation, these having the least sensitivity to the serum. The cycle is repeated on the most advanced mutation until there is no further development.
Patients receive uproleselan IV over 1 hour Q12H on days 1-7, azacitidine IV or SC QD on days 1-7, and venetoclax PO QD on days 1-28. Beginning cycle 5, patients achieving MLFS or better response, may receive azacitidine IV or SC QD and uproleselan IV over 1 hour QD on days 1-6 and 8 or days 1-5 and 8-9 or days 1-5. Treatment with uproleselan repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Cycles with azacitidine and venetoclax repeat every 28 days in the absence of disease progression and unacceptable toxicity.
Dental instrument for applying decay attacking fluid to teeth has a tubular member to conduct fluid from a supply to a working end which is formed as a spoon excavator which has side surfaces outwardly diverging from the contour of the tubular member, a curved terminating surface, a flat top and a depressed bottom surface. Used for administration of N-haloamine or similar soln. to dental caries or plaque to effect dissoln. Spoon end permits lifting up of areas of carious matl. to provide better access to the caries by the liq. while being easier to use and more comfortable to the patient than prior used hypodermic syringe needles.
Stroke, MI, and cardiovascular death (major adverse cardiovascular events [MACE]) have been reported in adults taking ZELNORM who had an increased risk of developing an adverse cardiovascular event based on their medical history [see Adverse Reactions (6.1)].

ZELNORM is contraindicated in patients with a history of MI, stroke, TIA, or angina [see Contraindications (4)]. Assess female patients less than 65 years of age for a history of cardiovascular disease and cardiovascular risk factors prior to treatment with ZELNORM [see Adverse Reactions (6.1)]. The potential risks of treatment must be balanced with expectations in improvements in symptoms of IBS-C.

Discontinue ZELNORM in patients who experience an MI, stroke, TIA, or angina [see Contraindications (4)]. Evaluate the risks and benefits of continued use of ZELNORM in patients who develop clinical or other evidence of cardiovascular ischemic heart disease (e.g., coronary artery disease) and/or experience changes in health status that could increase cardiovascular risk during treatment with ZELNORM.
This study aims to demonstrate that demographics combined with biometrics can be used to predict obesity related chronic disease risk and produce a health risk score that outperforms body mass index (BMI)-the most commonly used biomarker for obesity. We propose training an ensemble of small neural networks to fuse demographics and biometrics inputs. The categorical outputs of the networks are then turned into a multi-dimensional risk map, which associates diverse inputs with stratified, output health risk. Our ensemble model is optimized and validated on disjoint subsets of nationally representative data (N~100,000) from the National Health and Nutrition Examination Survey (NHANES). To broaden applicability of the proposed method, we consider only non-invasive inputs that can be easily measured through modern devices. Our results show that: (a) neural networks can predict individual conditions (e.g., diabetes, hypertension) or the union of multiple (e.g., nine) health conditions; (b) Softmax model outputs can be used to stratify individual- or any-condition risk; (c) ensembles of neural networks improve generalizability; (d) multiple-input models outperform BMI (e.g., 75.1% area under the receiver operator curve for eight-input, any-condition models compared to 64.2% for BMI); (e) small neural networks are as effective as larger ones for the inference tasks considered; the proposed models are small enough that they can be expressed as human-readable equations, and they can be adapted to clinical settings to identify high-risk, undiagnosed populations.
Losartan potassium may be administered with other antihypertensive agents, and with or without food.

Dosing must be individualized. The usual starting dose of losartan potassium is 50 mg once daily, with 25 mg used in patients with possible depletion of intravascular volume (e.g., patients treated with diuretics) (see WARNINGS, Hypotension - Volume-Depleted Patients) and patients with a history of hepatic impairment (see PRECAUTIONS, General). Losartan potassium can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg.

If the antihypertensive effect measured at trough using once-a-day dosing is inadequate, a twice-a-day regimen at the same total daily dose or an increase in dose may give a more satisfactory response. The effect of losartan is substantially present within one week but in some studies the maximal effect occurred in 3-6 weeks (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Hypertension).

If blood pressure is not controlled by losartan potassium alone, a low dose of a diuretic may be added. Hydrochlorothiazide has been shown to have an additive effect (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Hypertension).

No initial dosage adjustment is necessary for elderly patients or for patients with renal impairment, including patients on dialysis.
BACKGROUND: Treatment of diabetic neuropathic pain does not change the natural history of neuropathy. Improved glycemic control is the recommended treatment in these cases, given that no specific treatment for the underlying nerve damage is available, so far. In the present study, the potential neuroprotective effect of pentoxifylline in streptozotocin (50 mg/kg) induced diabetic neuropathy in rats was investigated.
METHODS: Pentoxifylline was administered at doses equivalent to 50, 100 & 200 mg/kg, in drinking water, starting one week after streptozotocin injection and for 7 weeks. Mechanical allodynia, body weight and blood glucose level were assessed weekly. Epidermal thickness of the footpad skin, and neuroinflammation and vascular alterations markers were assessed.
RESULTS: Tactile allodynia was less in rats that received pentoxifylline at doses of 100 and 200 mg/kg (60 % mechanical threshold increased by 48 % and 60 %, respectively). The decrease in epidermal thickness of footpad skin was almost completely prevented by the same doses. This was associated with a decrease in spinal tumor necrosis factor alpha (TNFα) and nuclear factor kappa B levels and a decrease in microglial ionized calcium binding adaptor molecule 1 immunoreactivity, compared to the control diabetic group. In sciatic nerve, there was decrease in TNF-α and vascular endothelial growth factor levels and intercellular adhesion molecule immunoreactivity.
CONCLUSION: Pentoxifylline showed a neuroprotective effect in streptozotocin-induced diabetic neuropathy, which was associated with a suppression of both the inflammatory and vascular pathogenic pathways that was not associated with a hypoglycemic effect. Thus, it may represent a potential neuroprotective drug for diabetics.